Testosterone Replacement for Male Opioid Agonist Maintained Patients
CompletedPhase 1, Phase 2NCT01873989
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is designed to develop an effective treatment intervention for chronic pain, symptomatic hypogonadism, and opioid addiction
Study details
- Official title
- Testosterone Replacement for Male Opioid Agonist Maintained Patients
- Conditions
- Chronic Pain
- Opioid Addiction
- Symptomatic Hypogonadism
- Interventions
- Drug: Testosterone replacement
- Other: Waitlist control
- Sponsor
- Yale University
- Start date
- 2012-04
- Primary completion
- 2015-01
- Sex
- Male
- Age range
- from 18 Years to 50 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Between 18 and 50 years of age * Male buprenorphine- or methadone-maintained patients at the APT Foundation * Moderate to severe chronic pain * Meet criteria for symptomatic hypogonadism * Understand English * Interested in receiving testosterone replacement Exclusion Criteria: * Current suicide or homicide risk * Life-threatening or unstable medical condition * Known or suspected prostate or chest cancer or history of polycythemia
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01873989